MUSCARINIC RECEPTOR AGONISTS Russian patent published in 2019 - IPC C07D471/10 C07D498/10 A61K31/444 A61K31/55 A61P25/00 

FIELD: chemistry.

SUBSTANCE: invention relates to formula (1a)

,

where: m is 1 or 2; p is 0 or 1; q is 0 or 1; W is C or N; Z is CH₂, N or O; Y is O, S or CH₂; X¹ and X² are saturated hydrocarbon groups, which together contain a total of five to nine carbon atoms and which are bonded in such a way that the moiety: forms a bridged bicyclic ring system; R¹ may be H, C_1-6 alkyl group optionally substituted with 1 to 3 fluorine atoms, or CH₂-W^a, where is W^a is a 6-membered aryl ring or pyridyl ring; R² can independently be H, C_1-6 alkyl group optionally substituted with 1 to 3 fluorine atoms, or CH₂-W^a, where W^a is a 6-membered aryl ring or pyridyl ring; R³ can independently be H, OH or C_1-6 alkyl group where one carbon atom is optionally substituted with a heteroatom selected from O; R⁴ may be H, optionally substituted C_1-5 alkyl or C_1-5 alkynyl, wherein the optional substituent is one fluorine atom; and if Z is O, R³ represents H or its pharmaceutically acceptable salt, which are agonists of the muscarinic receptor M₁.

EFFECT: treatment of Alzheimer's Disease, schizoprenia, cognitive disorders and other diseases mediated by the muscarinic M1/M4 receptors, as well as the treatment or alleviation of pain.

24 cl, 1 dwg, 4 tbl